Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Combatting Bladder Cancer by Inducing Epithelial Turnover

Funder: National Cancer Institute

Funding period
USD 204 K
Funding amount
Abstract
Abstract Bladder cancer is the 5th most frequent cancer in the US1. The most common histologic type of bladder cancer is urothelial carcinoma and it presents often as non-muscle invasive (NMIBC) form. The initial treatment for NMIBC is transurethral resection (TUR). However, over 70% of these patients will develop tumor recurrence with 25% showing progression to muscle-invading disease within 5 years of TUR. Currently, intravesicular BCG-based immunotherapy and chemotherapy are widely used as adjuvant therapies after TUR, but their effectiveness is limited, due to side effects and/or the inability of therapeutic agents to penetrate the bladder mucosa. Thus there exists a dire need for new strategies as adjunct therapy for bladder cancer. Recently, the whole scale exfoliation of the superficial epithelium mediated by the bladder to reduce bacterial numbers during infection was found to be a specific mast cell (MC) mediated activity. Further it was possible to activate whole scale exfoliation of the bladder epithelium by merely administering a MC activator in the bladder lumen. Although a highly efficient re-epithelization program exists for bladder epithelium recovery, addition of a GAG layer to the exposed bladder wall soon after exfoliation was found to significantly enhance the speed and intensity of bladder recovery. In view of this ability to trigger rapid turnover of the bladder epithelium, we hypothesize that safely inducing bladder epithelial turnover is a powerful way to prevent recurrence of bladder cancer. Here we plan to Investigate if inducing epithelial turnover with MC activators in the bladder will reduce/eliminate tumors in the bladders of mice. We will also Investigate if administering a GAG matrix containing growth promoting and/or anti-inflammatory agents will accelerate reepithelization following induced epithelial loss.
Similar projects All >
Sorted by: Start Date
Project list item
Investigating underlying molecular mechanisms of epigenetic therapies in muscle-invasive bladder cancer

Bladder Cancer Advocacy Network to Swathi Ramakrishnan

USD 1,700
2019 - 2019
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2019 - 2020
Project list item
Identifying Immunological Basis for Bladder Cancer Sex Bias

Canadian Institutes of Health Research to Hyunwoo Kwon, Zihai Li

USD 26,219
2019 - 2022
Project list item
Chromatin Modifier Gene Mutation and Enhancer Dysfunction in Bladder Cancer

National Cancer Institute to BYRON H LEE

USD 243,205
2019 - 2024

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Basic Science